Expert interviewed/The First Affiliated Hospital of Guangzhou University of Chinese Medicine The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine Deputy Chief Physician of Breast Surgery Huang Mei & Chief Physician of Gynecology Department Zeng Cheng
ã€Breast examination】
B ultrasound, molybdenum palladium, MRI examination have their own advantages
Breast cancer has always been called a female killer. How can we detect breast cancer early? Huang Mei said that if the immediate family members have breast cancer patients, or have a history of benign breast tumors such as breast fibroadenoma, or endocrine system diseases such as thyroid disease, the incidence of breast cancer may be higher than normal crowd.
For women under the age of 40, if it belongs to the high-risk group of breast cancer mentioned above, it is best to do a routine physical examination of the breast every year. Routine examination includes doctor's palpation and B-ultrasound examination of the mammary gland, and molybdenum target can be selected if necessary. Some people think that if you do a B-mode ultrasound, you do not need a doctor to palpate. Huang Mei explains that neither of them can replace one another. In clinical practice, this may happen. Some B-mode ultrasonography may not have obvious specificity, but there are Experienced doctors can find it through palpation. For breast B ultrasound, she suggested that the best color B ultrasound, color B ultrasound than black and white B ultrasound resolution is high, but also dynamic observation of blood flow changes to improve inspection accuracy. For women under the age of 40, who are not at high risk, it is recommended that they still insist on regular medical examinations.
For women over the age of 40, it is best to perform a B-ultrasound and a molybdenum-palladium test once a year. It is also often the case that women do not need to do B-mode ultrasound if they have done molybdenum-palladium tests. Huang Mei explained that the principle of this kind of inspection is different. One is to use ultrasound, and the other is to use X-rays to evaluate the health of breasts from different perspectives. B-ultrasound is more advantageous for the discovery of cystic breast disease, and molybdenum-palladium has an advantage in evaluating breast calcified lesions.
Huang Mei added that for women with conditions, they can also choose to do mammography. The advantage of this inspection is that it is basically harmless to the human body, and it is highly sensitive. Even the smallest lesions can be found. The disadvantage is that each inspection takes longer and costs more. Although the susceptibility of MRI examination is high, it cannot completely replace B-mode ultrasound and molybdenum-palladium. Because these two examinations have been introduced earlier, they have their own advantages.
â— Breast examination memorandum
Best time: The best time to check the breast is usually about 7-10 days after the end of menstruation, because the effect of estrogen on the mammary gland is smaller, the breast is in a relatively stable period, and the lesion or abnormality of the breast is more likely to be affected. Find. Postmenopausal women are free to choose the time for the breast examination.
Clothing: Dresses that are easy for doctors to check, and avoid wearing dresses or jumpsuits.
Palbociclib is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
It was reviewed and approved under the Food and Drug Administration`s (FDA) accelerated Priority Review and Breakthrough Therapy designation programs on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor positive advanced breast cancer.
We produce a series of complete intermediates for Palbociclib, intermediate I (CAS No. 571188-59-5), intermediate II (CAS No. 1013916-37-4) and intermediate III (CAS No. 1016636-76-2) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.
Palbociclib Intermediates,Cas 571188-59-5,Cas 1013916-37-4,Cas 1016636-76-2
Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com